key: cord-0795226-9x7c8acx
authors: Damme, Ellen Van; De Meyer, Sandra; Bojkova, Denisa; Ciesek, Sandra; Cinatl, Jindrich; De Jonghe, Steven; Jochmans, Dirk; Leyssen, Pieter; Meng, Christophe Buyck; Neyts, Johan; Van Loock, Marnix
title: In vitro activity of itraconazole against SARS‐CoV‐2
date: 2021-03-05
journal: J Med Virol
DOI: 10.1002/jmv.26917
sha: e8b18cdaecb50ef383016272ded14de7f42831fb
doc_id: 795226
cord_uid: 9x7c8acx

Although vaccination campaigns are currently being rolled out to prevent coronavirus disease (COVID‐19), antivirals will remain an important adjunct to vaccination. Antivirals against coronaviruses do not exist, hence global drug repurposing efforts have been carried out to identify agents that may provide clinical benefit to patients with COVID‐19. Itraconazole, an antifungal agent, has been reported to have activity against animal coronaviruses. Using cell‐based phenotypic assays, the in vitro antiviral activity of itraconazole and 17‐OH itraconazole was assessed against clinical isolates from a German and Belgian patient infected with SARS‐CoV‐2. Itraconazole demonstrated antiviral activity in human Caco‐2 cells (EC(50) = 2.3 µM; MTT assay). Similarly, its primary metabolite, 17‐OH itraconazole, showed inhibition of SARS‐CoV‐2 activity (EC(50) = 3.6 µM). Remdesivir inhibited viral replication with an EC(50) = 0.4 µM. Itraconazole and 17‐OH itraconazole resulted in a viral yield reduction in vitro of approximately 2‐log(10) and approximately 1‐log(10), as measured in both Caco‐2 cells and VeroE6‐eGFP cells, respectively. The viral yield reduction brought about by remdesivir or GS‐441524 (parent nucleoside of the antiviral prodrug remdesivir; positive control) was more pronounced, with an approximately 3‐log(10) drop and >4‐log(10) drop in Caco‐2 cells and VeroE6‐eGFP cells, respectively. Itraconazole and 17‐OH itraconazole exert in vitro low micromolar activity against SARS‐CoV‐2. Despite the in vitro antiviral activity, itraconazole did not result in a beneficial effect in hospitalized COVID‐19 patients in a clinical study (EudraCT Number: 2020‐001243‐15). This article is protected by copyright. All rights reserved.

The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) has been declared a global pandemic. 1,2 SARS-CoV-2 is a betacoronavirus, which are enveloped viruses containing single-strand, positive-sense RNA. 3 Since COVID-19 emerged in humans in late December 2019, 4 aside from a significant Accepted Article economic loss, more than one million deaths have been reported worldwide, driving urgently the need to identify potential vaccines and therapies.

Given that therapeutic options for antiviral treatment of SARS-CoV-2 remain limited, research has initially focused on repurposing available drugs that have demonstrated antiviral activity against coronaviruses. As part of such an initiative, itraconazole was identified as a potential candidate. Itraconazole has been described previously to have activity in an in vitro screen using a luciferase reporter-expressing recombinant murine betacoronavirus, 5 as well as against a feline alphacoronavirus that causes feline infectious peritonitis. 6 Furthermore, in vitro and in vivo activity has been described against other respiratory viruses, such as influenza A and human rhinovirus. 7, 8 Itraconazole is a member of the triazole group of broad-spectrum antifungals, 9 with a well-established efficacy and safety profile. [8] [9] [10] [11] [12] The primary mechanism of its antifungal action is the inhibition of ergosterol biosynthesis, by acting on the oxysterolbinding protein (OSBP). [13] [14] [15] [16] Since ergosterol is closely related to cholesterol, it has been suggested that also in mammalian cells, itraconazole acts as a cholesterol trafficking inhibitor resulting in disruption of the cholesterol-enriched membranes and thus inhibition of virus replication. 6, 8, 17 However, a role in interferon priming has also been suggested as a contributing factor to the antiviral activity. 18 In an attempt to identify therapeutic options for treating COVID-19 patients, the in vitro antiviral activities of itraconazole, and its metabolite 17-OH itraconazole were investigated in Caco-2 and VeroE6-eGFP cells infected with SARS-CoV-2, isolated from COVID-19 patients. 17-OH itraconazole diluted in MEM without FBS was added in four-fold dilutions to a concentration range of 0.02 μM to 100 μM and remdesivir diluted in MEM without FBS in four-fold dilutions was added to a concentration range of 0.02 μM to 100 μM. Cells were incubated for 48 hours; the CPE was then visually scored by two independent laboratory technicians. In addition, CPE was also assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay, performed according to the manufacturer's instructions. Optical densities were measured at 560/620 nm in a Multiskan Reader (MCC/340 Labsystems). Two series of three independent experiments (or one series of three experiments for 17-OH-itraconazole), each containing three replicates, were performed. Data were analyzed by four-parameter curve-fitting from a dose-response curve using GraphPad Prism (version 7.00) to calculate the EC 50 (concentration of the compound that inhibited 50% of the infection) based on visual CPE scoring or the MTT assay.

Cell viability in Caco-2 cells was measured following administration of each of the compounds or metabolites under investigation over the range of concentrations in the absence of virus using the Rotitest Vital (Roth, Karlsruhe, Germany) test according to manufacturer's instructions, as previously described. 21 All assays were performed three times independently in triplicate, this was performed twice (once for 17-OH-Accepted Article itraconazole). Data were analyzed by four-parameter curve-fitting from a dose-response curve using GraphPad Prism (version 7.00) to calculate the CC 50 (cytotoxic concentration of the compound that reduced cell viability to 50%). 

Independent experiments with triplicate measurements were performed with itraconazole (n = 6), 17-OH itraconazole (n = 3) and remdesivir (n = 6). In Caco-2 cells, itraconazole resulted in a dose-dependent inhibition of SARS-CoV-2-FFM1 measured by visual scoring of inhibition of CPE with an EC 50 = 1.5 μM (Figure 1 ; Table 1 In VeroE6-eGFP cells, a concentration of 1 µM itraconazole resulted in a ~1-log 10 reduction in vRNA levels ( Figure 3 ). This reduction was also observed at higher concentrations. As in Caco-2 cells, GS-441524 proved more potent in reducing vRNA This article is protected by copyright. All rights reserved.

Accepted Article than itraconazole. At a concentration of 3.7 µM, GS-441524 reduced vRNA load by >4 log 10 to undetectable levels. At concentrations of 10 µM and higher, 17-OH itraconazole resulted in limited activity, but VeroE6-eGFP cell viability was markedly affected ( Figure   3 ).

While a number of vaccines are available, for the moment there are no antivirals for the prevention of COVID-19 and only a limited number of antivirals for the treatment of COVID-19. 22 Given the great unmet need to identify potential treatments for COVID-19, and the fact that a de novo drug development project will take many years to bring a drug to patients, efforts have been expedited into the in vitro screening of compounds already on the market, or in late-stage development. In such an effort, itraconazole was identified, with single digit micromolar activity in Caco-2 cells. Itraconazole was first approved (in the US) in 1992 as an oral treatment for a number of fungal infections in immunocompromised and non-immunocompromised patients, with a well-established safety profile. 11 These experiments demonstrated that itraconazole inhibits in vitro SARS-CoV-2 replication in Caco-2 cells, an established cell line for studying SARS-CoV infections. 1, 23 The EC 50 values for inhibition of virus-induced CPE formation is in the low micromolar range and in that respect, is only around five-fold higher than that of remdesivir. The Itraconazole has documented activity against several enteroviruses, including rhinovirus. 8, 15 Further, at a dose of 5.7 mg/kg, itraconazole resulted in improved mortality and a lower viral load in mice that had been infected with human influenza (strain PR8M) compared with the control group. 7 As an antifungal agent, itraconazole inhibits fungal ergosterol biosynthesis, through inhibition of a cytochrome P450 enzyme, lanosterol-14-alpha-demethylase. [13] [14] [15] [16] It is also thought to interfere with cholesterol homeostasis and de novo synthesis in the host's cells through inhibition of this same enzyme, thereby influencing the virus/host cell interaction. 17, [25] [26] [27] The antiviral effect of itraconazole may be, at least in part, based on such a mechanism. Itraconazole impairs cholesterol trafficking and blocks late endosomal/lysosomal export of cholesterol to the plasma membrane through NPC intracellular cholesterol transporter 1 (NPC1) leading to cholesterol accumulation in subcellular compartments. 8, 16, [25] [26] [27] [28] In turn, elevated cholesterol levels in the endosomal membrane impede fusion of the viral lipid envelope and prevent viral genome transfer into the host cell cytosol. 7, 29 It has been postulated that such changes in cellular cholesterol are linked with the host's immune response. 30 Disruption of cholesterol biosynthesis has been shown to upregulate type I interferons and thereby accelerate the virus-induced interferon-mediated host cell response. 7, 30 It has also been suggested that itraconazole may have antiviral effects through proteins other than NPC1. 6 In This article is protected by copyright. All rights reserved.

enteroviruses, itraconazole has been shown to inhibit vRNA replication by OSBP, which is responsible for trafficking of cholesterol and phosphatidylinositol-4-phosphate between membranes, thus also affecting the membranes of the replication complex. 15, 16 Since coronaviruses result in the formation of intracellular viral replicative organelles within the endoplasmic reticulum that drive the viral replication cycle, [31] [32] [33] it is possible that inhibition of OSBP may cause detrimental changes to replicative organelle membranes. 15, 16, 33, 34 Although it remains to be confirmed how itraconazole may inhibit the replication cycle of coronaviruses, it is conceivable that it acts through multiple mechanisms. 7, 17 As a lipophilic compound, itraconazole has high bioavailability and extensive distribution throughout the lung, kidney, epidermis and brain. 9 Itraconazole is predominantly metabolized by the cytochrome P450 3A4 isoenzyme system, forming many metabolites. 35, 36 The main metabolite produced is 17-OH itraconazole, which also has considerable antifungal activity. 35 Following administration of itraconazole 200-mg bid, itraconazole and its 17-OH hydroxy-metabolite have been shown to reach mean maximal plasma concentrations of 2282 and 3488 ng/mL (~3.2 μM and ~4.8 μM) and a C trough of 1855 and 3349 ng/ml (~2.6 μM and ~4.7 μM), respectively, which is close to the EC 50 for inhibition of virus-induced CPE. Both the parent drug and metabolite have long half-lives (64 and 56 hours, respectively). 11 In conclusion, itraconazole and its metabolite, 17-OH itraconazole show in vitro activity against SARS-CoV-2. Based on these in vitro findings, a clinical study in hospitalized COVID-19 patients was initiated by UZ Leuven in March 2020. 37 This clinical study was ended prematurely because of futility. 38 Other studies in non-hospitalized patients have not been conducted. 

Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

A novel coronavirus from patients with pneumonia in China

A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs

Antiviral activity of itraconazole against type I feline coronavirus infection

The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo

Therapeutic and prophylactic activity of itraconazole against human rhinovirus infection in a murine model

Azole antifungal agents: emphasis on new thiazoles

Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth

Itraconazole: What clinicians should know?

The ergosterol biosynthesis pathway, transporter genes, and azole resistance in Aspergillus fumigatus

Sterol 14α-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms

Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein

Structure-activity relationship study of itraconazole, a broad-range inhibitor of picornavirus replication that targets oxysterol-binding protein (OSBP)

The cholesterol transport inhibitor U18666A inhibits type I feline coronavirus infection

The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry

Simultaneous targeting of NPC1 and VDAC1 by itraconazole leads to synergistic inhibition of mTOR signaling and angiogenesis

Late endosomal/lysosomal cholesterol accumulation is a host cell-protective mechanism inhibiting endosomal escape of influenza A virus. mBio

Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling

Three-dimensional imaging of viral infections

Membranous replication factories induced by plus-strand RNA viruses

Does form meet function in the coronavirus replicative organelle?

Endocytic pathway of feline coronavirus for cell entry: differences in serotype-dependent viral entry pathway

Stereospecific metabolism of itraconazole by CYP3A4: Dioxoalane ring scission of azole antifungals

Making sense of itraconazole pharmockinetics

Covid-19: A randomized, open-label, adaptive, proof-of-concept clinical trial of new antiviral drug candidates against SARS-CoV-2

Itraconazole for COVID-19: preclinical studies and a proof-of-concept pilot clinical study. Preprints with the Lancet